Hereditary Cancer Panel denied as non-formulary by Carelon (formerly AIM)?

NCCN-aligned for hereditary cancer testing. Pre-test genetic counseling required for many panels. Avalon overlap in some plans.

GC by ABGC-certified counselor (telegenetics qualifies). NCCN BOP/COL footnotes endorse multi-gene panels when >1 syndrome on differential. Reroute to in-network lab if denial is contractual.

## Why Carelon Denied Your Hereditary Cancer Panel as Non-Formulary

Although "formulary" language is most commonly associated with prescription drugs, Carelon (formerly AIM Specialty Health) and the health plans it manages sometimes apply an analogous preferred-laboratory or preferred-test framework to genetic testing. A non-formulary denial for a hereditary cancer panel typically means one of the following: the laboratory that performed the test is not in the plan's preferred lab network, the specific panel configuration is not on the plan's covered-test list, or the test was ordered without required prior authorization through an in-network pathway.

## Why This Denial Is Appealable

Non-formulary denials for genetic testing are often procedural rather than clinical. If there is no in-network laboratory that offers the medically necessary panel, or if the in-network alternative would provide a clinically inferior result for your specific indication, you have a strong basis for a medical-necessity exception. Plans are required under ACA non-discrimination and medical necessity standards to provide access to covered benefits when in-network alternatives are inadequate.

## Federal Appeal Framework

• Internal Appeal: ACA and ERISA §503 provide the right to a full-and-fair internal appeal. File within the deadline on your denial letter.
• External Review: Under ACA §2719, a final internal denial entitles most members to independent external review by an accredited IRO, generally within four months of the final internal denial. Expedited review is available for urgent cases.
• Network Adequacy: If no in-network laboratory performs the required panel, raise a network adequacy complaint simultaneously with your insurance commissioner — this can accelerate resolution.

## Concrete Appeal Steps and Timeline

1. Identify the in-network alternative Carelon or the plan proposes. Obtain its specific gene list and compare it against the ordered panel. 2. Have your prescriber document why the in-network alternative is clinically insufficient for your specific indication. 3. Request an exception on medical necessity grounds, citing the gap between the in-network option and your clinical need. 4. File internal appeal within the stated deadline. 5. File external review if internal appeal is denied.

## Documentation to Gather

• Prescriber letter explaining why the specific laboratory or panel configuration was selected and why an in-network alternative is clinically inadequate
• Comparison of gene sets between the ordered panel and any proposed in-network substitute
• Diagnosis and clinical indication records supporting the specific panel ordered
• Applicable guideline from the relevant professional organization (such as NCCN) supporting the clinical indication — obtain directly from that organization
• Documentation that prior authorization was either obtained or that the urgency of the clinical situation precluded prior authorization

## Criteria-Mapping Structure

For each basis of the non-formulary denial, document your response:

| Denial Basis | Your Supporting Evidence | |---|---| | Out-of-network laboratory used | Evidence of no in-network equivalent; prescriber's rationale for lab selection | | Panel not on covered-test list | Guideline support for the specific panel; prescriber letter on clinical necessity | | No prior authorization obtained | Auth documentation or explanation of why urgent circumstances prevented prior auth |

A well-documented exception request that shows the in-network alternative is clinically inferior is the most effective path to overturning this type of denial.